LCM
VNDA icon

Legato Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Legato Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,778
Closed -$109K – 533
2022
Q4 		$109K Buy
+14,778
New +$144K 0.02% 472

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Legato Capital Management's VNDA Position: Q1 2023 in Review

Legato Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2023, closing a stake of 14,778 shares — an estimated $109K sold.

Legato Capital Management first reported a position in VNDA in Q4 2022 and held it in 1 quarter. The position peaked at $109K in Q4 2022. 177 funds tracked by Wall St. Rank hold VNDA as of Q1 2023.

  • Legato Capital Management reported no remaining Vanda Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Legato Capital Management sold 14,778 Vanda Pharmaceuticals shares in Q1 2023, an estimated $109K.
  • Legato Capital Management first reported a position in Vanda Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Legato Capital Management's Vanda Pharmaceuticals position peaked at $109K in Q4 2022.
  • 177 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2023.

Based on Legato Capital Management's 13F filing for Q1 2023, filed 25 May 2023.